Feedback / Questions
CID-078 - Circle Pharma
https://www.businesswire.com/news/home/20241209316558/en/Circle-Pharma-Presents-Promising-Preclinical-Data-on-First-in-Class-Oral-Macrocycle-Cyclin-AB-RxL-Inhibitor-CID-078-at-the-San-Antonio-Breast-Cancer-Symposium-2024
Dec 9, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next